{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Invasive+Pulmonary+Aspergillosis",
    "query": {
      "condition": "Invasive Pulmonary Aspergillosis"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 11,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Invasive+Pulmonary+Aspergillosis&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T02:55:37.194Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04240886",
      "title": "Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Invasive Fungal Infections"
      ],
      "interventions": [
        {
          "name": "fosmanogepix",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Basilea Pharmaceutica",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2020-01-04",
      "completion_date": "2022-05-09",
      "has_results": true,
      "last_update_posted_date": "2025-09-16",
      "last_synced_at": "2026-06-11T02:55:37.194Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Durham, North Carolina",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04240886"
    },
    {
      "nct_id": "NCT03672292",
      "title": "Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Invasive Pulmonary Aspergillosis"
      ],
      "interventions": [
        {
          "name": "SCY-078",
          "type": "DRUG"
        },
        {
          "name": "Voriconazole",
          "type": "DRUG"
        },
        {
          "name": "Oral Placebo Tablets",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Scynexis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2019-01-22",
      "completion_date": "2023-03-27",
      "has_results": true,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-06-11T02:55:37.194Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03672292"
    },
    {
      "nct_id": "NCT03327727",
      "title": "VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Invasive Aspergillosis",
        "Invasive Pulmonary Aspergillosis"
      ],
      "interventions": [
        {
          "name": "Investigational Agent: VL-2397",
          "type": "DRUG"
        },
        {
          "name": "Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2018-02-20",
      "completion_date": "2019-01-14",
      "has_results": false,
      "last_update_posted_date": "2019-02-27",
      "last_synced_at": "2026-06-11T02:55:37.194Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Sacramento, California + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03327727"
    },
    {
      "nct_id": "NCT03059992",
      "title": "Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Invasive Candidiasis",
        "Mucocutaneous Candidiasis",
        "Coccidioidomycosis",
        "Histoplasmosis",
        "Blastomycosis",
        "Chronic Pulmonary Aspergillosis",
        "Allergic Bronchopulmonary Aspergillosis",
        "Invasive Pulmonary Aspergillosis",
        "Recurrent Vulvovaginal Candidiasis",
        "Other Emerging Fungi"
      ],
      "interventions": [
        {
          "name": "Ibrexafungerp",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Scynexis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 233,
      "start_date": "2017-04-01",
      "completion_date": "2023-08-25",
      "has_results": true,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-06-11T02:55:37.194Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Sacramento, California • San Francisco, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03059992"
    },
    {
      "nct_id": "NCT00923832",
      "title": "Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Immunocompromised Host",
        "Invasive Pulmonary Fungal Infection",
        "Invasive Pulmonary Aspergillosis",
        "Invasive Pulmonary Zygomycosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "1 Year to 99 Years"
      },
      "enrollment_count": null,
      "start_date": "2009-03-30",
      "completion_date": "2009-11-23",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-06-11T02:55:37.194Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00923832"
    },
    {
      "nct_id": "NCT05238116",
      "title": "Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Refractory IPA"
      ],
      "interventions": [
        {
          "name": "PC945",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pulmocide Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2022-06-14",
      "completion_date": "2025-12-29",
      "has_results": true,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-06-11T02:55:37.194Z",
      "location_count": 15,
      "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 10 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05238116"
    },
    {
      "nct_id": "NCT04707703",
      "title": "Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Severe Acute Respiratory Syndrome Coronavirus 2",
        "Aspergillosis Invasive"
      ],
      "interventions": [
        {
          "name": "Isavuconazonium Injection [Cresemba]",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jeffrey Jenks, MD, MPH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2021-03-16",
      "completion_date": "2021-10-25",
      "has_results": false,
      "last_update_posted_date": "2022-11-25",
      "last_synced_at": "2026-06-11T02:55:37.194Z",
      "location_count": 3,
      "location_summary": "Orange, California • Sacramento, California • San Diego, California",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04707703"
    },
    {
      "nct_id": "NCT00940017",
      "title": "A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Aspergillosis",
        "Candidemia"
      ],
      "interventions": [
        {
          "name": "anidulafungin and voriconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2008-09",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2010-02-09",
      "last_synced_at": "2026-06-11T02:55:37.194Z",
      "location_count": 1,
      "location_summary": "Hartford, Connecticut",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00940017"
    },
    {
      "nct_id": "NCT04818853",
      "title": "COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Covid19",
        "Aspergillosis",
        "Fungal Infection"
      ],
      "interventions": [
        {
          "name": "Observation to monitor patients for these infections",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 219,
      "start_date": "2021-03-09",
      "completion_date": "2023-01-13",
      "has_results": false,
      "last_update_posted_date": "2026-01-16",
      "last_synced_at": "2026-06-11T02:55:37.194Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04818853"
    },
    {
      "nct_id": "NCT03827694",
      "title": "Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pulmonary Invasive Fungal Infections",
        "Pulmonary Invasive Aspergillosis"
      ],
      "interventions": [
        {
          "name": "Non-Invasive Testing for PIFI",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Arkansas Children's Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "120 Days",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "120 Days to 21 Years"
      },
      "enrollment_count": 400,
      "start_date": "2018-10-30",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-09-25",
      "last_synced_at": "2026-06-11T02:55:37.194Z",
      "location_count": 32,
      "location_summary": "Little Rock, Arkansas • La Jolla, California • Orange, California + 28 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03827694"
    }
  ]
}